行情

CBIO

CBIO

Brookfield再生能源
NASDAQ

实时行情|Nasdaq Last Sale

5.56
-0.21
-3.56%
交易中 12:30 11/12 EST
开盘
5.76
昨收
5.76
最高
5.77
最低
5.52
成交量
1.16万
成交额
--
52周最高
11.29
52周最低
4.520
市值
6,674.84万
市盈率(TTM)
-1.4024
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CBIO 新闻

  • 政治疑虑仍存 交易员押注英镑将在未来几个月走软
  • 环球外汇网官网.26分钟前
  • 美银将10年期美债收益率年底预估从1.25%上调至2%
  • 新浪美股.36分钟前
  • 外汇储备消耗严重 阿根廷或存严重的债务违约风险
  • 新浪美股.37分钟前
  • 芝加哥商业交易所确定明年1月13日发布比特币期权
  • FX168.1小时前

更多

所属板块

生物技术和医学研究
+0.15%
制药与医学研究
+0.46%

热门股票

名称
价格
涨跌幅

CBIO 简况

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
展开

Webull提供Catalyst Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。